Journal article
Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies
Abstract
BACKGROUND: Adalimumab, a fully human monoclonal antibody, binds to and neutralizes tumor necrosis factor.
OBJECTIVE: To provide an integrated review of efficacy and safety from adalimumab clinical trials in psoriasis.
Authors
Papp K; Okun M; Vender R
Journal
Journal of Cutaneous Medicine and Surgery, Vol. 13, No. 5_suppl, pp. s58–s66
Publisher
SAGE Publications
Publication Date
9 2009
DOI
10.2310/7750.2009.00022
ISSN
1203-4754